Unlike everyday supplements stocked in every health store, CJC-1295 moves through a global research peptide market that Cizer residents reach through online vendors. This matters because CJC-1295 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to mislabeled or underdosed compounds — and the vendor controls every quality variable. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide gives Cizer researchers the framework to verify sourcing options methodically and source verified-quality CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Cizer studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at very low concentrations. Community reputation in research forums is a complementary signal to COA verification — vendors with multi-year positive track records have earned that standing through repeat quality delivery. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Cizer
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the risk characterisation for this compound is based on preclinical evidence rather than regulated clinical data. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results stated as EU/mg and verify they are within the acceptable range for your research context. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
